217 related articles for article (PubMed ID: 390336)
21. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Libman I; Gawel MJ; Riopelle RJ; Bouchard S
Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
[TBL] [Abstract][Full Text] [Related]
22. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Rondot P; Ziegler M; Aymard N; Teinturier A
Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
[TBL] [Abstract][Full Text] [Related]
23. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Gawel M; Riopelle R; Libman I; Bouchard S
Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
[No Abstract] [Full Text] [Related]
24. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S;
Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014
[TBL] [Abstract][Full Text] [Related]
25. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
[TBL] [Abstract][Full Text] [Related]
27. The effects of combining carbidopa with levodopa for Parkinson's disease.
Martin WE; Tolosa ES; Loewenson RB; Lee MC; Resch JA; Baker AB
Geriatrics; 1975 Dec; 30(12):39-44. PubMed ID: 1104406
[No Abstract] [Full Text] [Related]
28. The Sydney multicentre study of Parkinson's disease. The first 18 months.
Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
[TBL] [Abstract][Full Text] [Related]
29. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
30. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
Bush DF; Liss CL; Morton A
Neurology; 1989 Nov; 39(11 Suppl 2):101-4; discussion 105. PubMed ID: 2685646
[TBL] [Abstract][Full Text] [Related]
31. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Olanow CW; Alberts MJ
Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
[No Abstract] [Full Text] [Related]
32. Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease.
Gilligan B; Hancock R
Med J Aust; 1975 Nov; 2(22):824-6. PubMed ID: 1207582
[TBL] [Abstract][Full Text] [Related]
33. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Goetz CG; Tanner CM; Gilley DW; Klawans HL
Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
[TBL] [Abstract][Full Text] [Related]
34. Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
Lieberman AN; Gopinathan G; Neophytides A; Pasternack P
N Y State J Med; 1986 Dec; 86(12):655-6. PubMed ID: 3468386
[No Abstract] [Full Text] [Related]
35. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Rinne UK; Rinne JO
Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
Bermejo Pareja F; Martínez-Martín P
Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
[No Abstract] [Full Text] [Related]
37. One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
Diamond SG; Markham CH
Adv Neurol; 1984; 40():537-9. PubMed ID: 6695633
[No Abstract] [Full Text] [Related]
38. Sinemet CR for Parkinson's disease.
Med Lett Drugs Ther; 1991 Oct; 33(854):92-3. PubMed ID: 1895993
[No Abstract] [Full Text] [Related]
39. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
Hutton JT; Morris JL
Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]